Formation Bio launches $600 million fund to advance clinical-stage drug assets
Formation Bio announced a $600 million drug development accelerator fund aimed at acquiring 10 to 15 Phase I or Phase II assets over the next three to five years. The company says it will use its AI systems and clinical operations team to advance the assets to key milestones within two to four years before selling them or partnering with large pharmaceutical companies. A wholly owned subsidiary will serve as the fund’s general partner, with Formation Bio committing its own capital. Limited partners include research foundations, endowments, hospitals and charities. The report says Formation Bio’s claimed AI development advantage has not been independently established. BCG’s 2024 figures put the Phase I success rate for AI-designed molecules at 80% to 90%, falling to about 40% at Phase II.
The fund is comparable in size to Formation Bio’s previous equity financing and nearly doubles its capital with little dilution to the parent, according to the report. It establishes a hybrid strategy combining pipeline arbitrage, AI-assisted asset selection, in-house clinical execution and fund financing, rather than a shift away from AI drug discovery.
本文旨在传递生命科学和医疗健康产业最新讯息，不是治疗方案和投资建议。
还在替药企运营临床试验时，一家名为 TrialSpark 的公司就动了自己买管线开发的念头，但得到的客户反馈却有些出乎意料：手里的药多到开发不起，已经发现的药也没那么值钱。
过去几年，AI 制药的资本和注意力大多流向药物发现。但分子造得越快，排在临床门口的队伍就越长：单个热门靶点的平均在研药物数量从 2000 年代的两三个增加到如今的七八个，PD-1 和 GLP-1 两个最热靶点的项目数甚至分别超过了 100 个。
大药企的仓库里，常年存放着一批因资源受限无法继续推进开发的候选药。TrialSpark 瞄准了这个缺口，顺势转型 AI 制药公司，并更名为 Formation Bio。
#Formation Bio#TrialSpark#Roivant Sciences#Axovant#OpenAI#Sanofi#a16z#Sequoia Capital#Boston Consulting Group#Insilico Medicine